Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

This study found that mild-to-moderate COVID-19 was not associated with worsening in patients with pre-existing alopecia areata.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

In this study, combining topical calcipotriol with mometasone results in greater improvement in alopecia areata treatment compared to using mometasone alone, as evidenced by a more significant reduction in SALT score over 24 weeks.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

In this study, Japanese patients with alopecia areata were found to have higher BMI and retinol intake, with retinol intake predicting severity of hair loss.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.

This study found that in patients with alopecia areata, serum granulysin levels decreased significantly after treatment with tofacitinib and correlated with reduced disease severity, suggesting serum granulysin as an indicator of immunological activity and response to therapy.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

In this study, researchers examined trichoscopic features in a cohort of Black patients with alopecia areata, identifying both common and novel characteristics, but found no statistical link between these features and the severity of alopecia.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

This study found that children with alopecia areata had significantly lower serum vitamin D levels than healthy controls.

This study found that vitamin D levels in children with autoimmune alopecia were often below optimal, but did not suggest a need for extra vitamin D screening beyond standard practices.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This study identified key dermoscopic markers such as yellow dots, black dots, broken hairs, and coudability hairs, which were associated with a poorer prognosis in alopecia areata patients.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

In this study, adding topical calcipotriol 0.005% to topical clobetasol 0.05% significantly improved treatment efficacy for Alopecia Areata compared to using clobetasol alone, as evidenced by a greater reduction in SALT scores over 24 weeks.